Table 2.
Univariate and multivariate analysis for PFS and OS
| Progression‐free survival | Overall survival | |||||||
|---|---|---|---|---|---|---|---|---|
| Mean, 95% CI | P‐value | HR (95%, CI) | P‐value | Mean, 95% CI | P‐value | HR (95%, CI) | P‐value | |
| Overall | 8.3 (5.8‐10.8) | 25.6 (20.8‐30.4) | ||||||
| Sex | ||||||||
| Male | 10.7 (6.6‐14.9) | 23.9 (17.5‐30.3) | ||||||
| Female | 6.7 (4.3‐9.2) | .092 | 1.4 (0.8‐2.5) | .243 | 28.3 (20.5‐36.1) | .077 | 0.8 (0.5‐1.4) | .558 |
| Age | ||||||||
| <60 y | 8.3 (5.0‐11.5) | 29.9 (26.7‐33.2) | ||||||
| ≥60 y | 8.6 (5.9‐11.3) | .219 | 22.1 (19.2‐25.1) | .048 | 1.5 (0.9‐2.3) | .113 | ||
| Tobacco exposure | ||||||||
| Nonsmoker | 6.9 (4.6‐9.4) | 23.1 (17.6‐28.6) | ||||||
| Smoker | 9.7 (5.6‐13.8) | .223 | 26.6 (18.9‐34.3) | .676 | ||||
| Wood smoke exposure | ||||||||
| Absent | 9.4 (6.2‐12.6) | 23.9 (18.3‐29.5) | ||||||
| Present | 5.0 (2.2‐7.8) | .087 | 1.4 (0.8‐2.6) | .197 | 26.9 (14.6‐39.2) | .549 | ||
| ECOG PS | ||||||||
| 0‐1 | 9.4 (7.0‐11.8) | 28.9 (26.2‐31.8) | ||||||
| 2+ | 3.9 (2.2‐5.7) | .001 | 2.8 (1.4‐5.4) | .003 | 19.4 (14.0‐24.7) | .001 | 2.4 (1.3‐4.4) | .003 |
| Disease stage | ||||||||
| IIIB | NR (NR) | NR (NR) | ||||||
| IV | 7.9 (5.4‐10.3) | .034 | 23.9 (19.0 −28.8) | .365 | ||||
| Histology | ||||||||
| Adenocarcinoma | 8.6 (6.2‐11.1) | 25.6 (20.8‐30.4) | ||||||
| Squamous | 5.3 (3.9‐6.6) | .331 | 18.2 (NR) | .973 | ||||
| Histological grade | ||||||||
| High‐Moderate | 9.7 (7.9‐11.6) | 27.5 (21.8‐33.3) | ||||||
| Low | 6.7 (4.2‐9.3) | .062 | 1.8 (1.0‐3.2) | .039 | 17.7 (14.1‐21.3) | .029 | 1.8 (1.1‐2.8) | .014 |
| Contralateral Lung metastases | ||||||||
| Absent | 9.4 (6.6‐12.2) | 23.9 (18.0‐29.8) | ||||||
| Present | 5.5 (4.6‐6.4) | .051 | 1.6 (0.9‐2.9) | .124 | 21.5 (12.4‐30.5) | .809 | ||
| CNS metastases | ||||||||
| Absent | 7.9 (5.7‐10.0) | 23.9 (18.7‐29.2) | ||||||
| Present | 9.4 (1.8‐17.0) | .693 | 22.1 (8.2‐36.1) | .734 | ||||
| Bone metastases | ||||||||
| Absent | 8.6 (5.6‐11.7) | 23.9 (18.8‐29.1) | ||||||
| Present | 6.8 (1.2‐12.4) | .197 | 23.1 (13.6‐32.5) | .955 | ||||
| CEA | ||||||||
| <5 pg/mL | 9.7 (7.6‐11.9) | 36.9 (18.5‐55.3) | ||||||
| ≥5 pg/mL | 7.2 (5.2‐9.3) | .486 | 23.9 (18.6‐29.3) | |||||
| EGFR status | ||||||||
| EGFRwt | 6.2 (4.1‐8.4) | 20.9 (17.1‐24.7) | ||||||
| EGFR+ | 10.8 (6.8‐14.9) | .06 | 0.7 (0.4‐1.2) | .156 | 39.8 (27.2‐52.3) | .001 | 0.4 (0.2‐0.8) | .004 |
| CD47 score | ||||||||
| Absent | 5.7 (4.5‐6.8) | 25.6 (16.5‐34.7) | ||||||
| Present | 9.3 (6.9‐11.7) | .409 | 26.3 (20.1‐32.4) | .912 | ||||
| CD47 score | ||||||||
| <150 | 7.9 (4.2‐11.5) | 23.3 (17.4‐29.2) | ||||||
| ≥150 | 8.9 (5.6‐12.2) | .936 | 27.5 (18.9‐36.2) | .976 | ||||
Abbreviations: CEA, Carcinoembryonic antigen; CI, Confidence interval; CNS, Central Nervous System; ECOG PS, Eastern cooperative oncology group performance status; EGFR, Epidermal Growth Factor; HsssR, Hazard ratio; NR, Not reach.